Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
94.2M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
15.3M
-
Shares change
-
+1.21M
-
Total reported value, excl. options
-
$383M
-
Value change
-
+$30.9M
-
Number of buys
-
39
-
Number of sells
-
-15
-
Price
-
$25.00
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) as of Q2 2019
69 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock as of Q2 2019.
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.3M shares
of 94.2M outstanding shares and own 16.26% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (3.38M shares), PERCEPTIVE ADVISORS LLC (2.59M shares), ORBIMED ADVISORS LLC (2.04M shares), RA CAPITAL MANAGEMENT, LLC (1.88M shares), BlackRock Inc. (932K shares), EVENTIDE ASSET MANAGEMENT, LLC (804K shares), VANGUARD GROUP INC (505K shares), JANUS HENDERSON GROUP PLC (500K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (490K shares), and PRICE T ROWE ASSOCIATES INC /MD/ (488K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.